Cysteine Hydrochloride is one of 642 small molecule programs targeting Neurotoxicity. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
401 competitors in Lymphoma
Cysteine Hydrochloride
Cabenuva
Norvir
Emend
Kenalog
Nuvigil
Elitek
Decadron
Solu-Medrol
Systemic Therapy
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Oct 22, 1986
CYSTEINE HYDROCHLORIDE
NDA NDA019523
Apr 16, 2019
ELCYS
NDA NDA210660
Dec 13, 2019
NOURESS
NDA NDA212535
Sources